Literature DB >> 33447884

Toxoplasma gondii infection in hospitalized people living with HIV in Spain, 1997 to 2015.

Marouane Menchi-Elanzi1, Asunción M Mayoral2, Javier Morales2, Hector Pinargote-Celorio3, Gregorio González-Alcaide4, José-Manuel Ramos-Rincón5,6.   

Abstract

Toxoplasma gondii infection was one of the most frequent AIDS-defining conditions in HIV-infected individuals until the advent of combination antiretroviral therapy. We aimed to assess the clinical load, coinfection, and mortality, as well as time trends for people living with HIV and hospitalized with Toxoplasma gondii infection, in Spain from 1997 to 2015. Retrospective observational analysis using the Spanish National Registry of Hospital Discharges. Information was retrieved for the study period using the International Classification of Diseases, 9th revision. There were 66,451,094 hospital admissions in Spain from 1997 to 2015, including 472,269 (0.71%) in people living with HIV. Toxoplasma gondii infection was registered in 9006 of these (overall prevalence 1.91%), making it the fifth most common opportunistic infection in hospitalized HIV-positive patients. Prevalence of Toxoplasma gondii infection declined in this group from 4.2% in 1997 to 0.8% in 2015 (p < 0.001), while mean age increased, from 35 years in 1997 to 44 years in 2015. The overall in-hospital mortality rate declined from 13.5% in 1997 to 8.9% in 2015, and it was higher in the concomitant presence of bacterial pneumonia (28.9% vs. 10.2%, p < 0.001), cryptosporidiosis (26.9% vs. 11.5%; p = 0.03), cytomegalovirus disease (18.2% vs. 11.2%, p < 0.001), Pneumocystis jiroveci pneumonia (31.5% vs. 10.5%, p < 0.001), leukoencephalopathy (19.8% vs. 11.78% p < 0.001), and wasting syndrome (29.3% vs 10.9%; p < 0.001). Toxoplasma gondii infection prevalence has significantly declined among hospitalized HIV-infected patients in Spain during the last two decades, coinciding with the widespread use of combination antiretroviral therapy.

Entities:  

Keywords:  HIV; Hospital admissions; Mortality; Opportunistic infections; Spain; Toxoplasma gondii infection; Toxoplasmosis

Mesh:

Year:  2021        PMID: 33447884     DOI: 10.1007/s00436-020-07007-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  18 in total

1.  Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.

Authors:  Jose M Miro; Juan C Lopez; Daniel Podzamczer; Jose M Peña; Juan C Alberdi; Esteban Martínez; Pere Domingo; Jaime Cosin; Xavier Claramonte; Jose R Arribas; Miguel Santín; Esteban Ribera
Journal:  Clin Infect Dis       Date:  2006-05-31       Impact factor: 9.079

2.  Admissions for imported and non-imported parasitic diseases at a General Hospital in Spain: A retrospective analysis.

Authors:  Guillermo Gironé; Claudia Mateo; Víctor Gaya; Jordi Usó; Carlos Mínguez; Bernardino Roca; José M Ramos
Journal:  Travel Med Infect Dis       Date:  2015-05-09       Impact factor: 6.211

3.  Spectrum of AIDS Defining Opportunistic Infections in a Series of 77 Hospitalised HIV-infected Omani Patients.

Authors:  Abdullah A Balkhair; Zakariya K Al-Muharrmi; Shyam Ganguly; Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

4.  Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection.

Authors:  Oluwatoyin Falusi; Audrey L French; Eric C Seaberg; Phyllis C Tien; D Heather Watts; Howard Minkoff; Eva Piessens; Andrea Kovacs; Kathryn Anastos; Mardge H Cohen
Journal:  Clin Infect Dis       Date:  2002-11-11       Impact factor: 9.079

Review 5.  HIV-Associated Neurologic Disorders and Central Nervous System Opportunistic Infections in HIV.

Authors:  Leah T Le; Serena S Spudich
Journal:  Semin Neurol       Date:  2016-09-19       Impact factor: 3.420

6.  The evolving mode of presentation of HIV-infected patients to health services of northern Spain: 1985 through December 1999.

Authors:  J Collazos; J Mayo; E Martinez
Journal:  AIDS Patient Care STDS       Date:  2001-02       Impact factor: 5.078

7.  Recommendations for diagnosis of shiga toxin--producing Escherichia coli infections by clinical laboratories.

Authors:  L Hannah Gould; Cheryl Bopp; Nancy Strockbine; Robyn Atkinson; Vickie Baselski; Barbara Body; Roberta Carey; Claudia Crandall; Sharon Hurd; Ray Kaplan; Marguerite Neill; Shari Shea; Patricia Somsel; Melissa Tobin-D'Angelo; Patricia M Griffin; Peter Gerner-Smidt
Journal:  MMWR Recomm Rep       Date:  2009-10-16

Review 8.  HIV.

Authors:  Jade Ghosn; Babafemi Taiwo; Soraya Seedat; Brigitte Autran; Christine Katlama
Journal:  Lancet       Date:  2018-07-23       Impact factor: 79.321

9.  Causes of hospitalization and predictors of HIV-associated mortality at the main referral hospital in Sierra Leone: a prospective study.

Authors:  Sulaiman Lakoh; Darlinda F Jiba; Joseph E Kanu; Eva Poveda; Angel Salgado-Barreira; Foday Sahr; Momodu Sesay; Gibrilla F Deen; Tom Sesay; Wadzani Gashau; Robert A Salata; George A Yendewa
Journal:  BMC Public Health       Date:  2019-10-21       Impact factor: 3.295

10.  Opportunistic diseases among HIV-infected patients: a multicenter-nationwide Korean HIV/AIDS cohort study, 2006 to 2013.

Authors:  Youn Jeong Kim; Jun Hee Woo; Min Ja Kim; Dae Won Park; Joon-Young Song; Shin Woo Kim; Jun Yong Choi; June Myung Kim; Sang Hoon Han; Jin-Soo Lee; Bo Youl Choi; Joo Shil Lee; Sung-Soon Kim; Mee-Kyung Kee; Moon Won Kang; Sang Il Kim
Journal:  Korean J Intern Med       Date:  2016-04-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.